`RESEARCH
`
`
`
`APPLICATION NUMBER:
`
`209091Orig1s000
`
`OFFICER/EMPLOYEE LIST
`
`
`
`
`
`
`Officer/Employee List
`
`NDA 209091
`
`
`
`
`
`
`
`
`
`Drug Name: Qtern ( dapagliflozn and saxagliptin) tablets
`
`
`Applicant: AstraZeneca
`
`
`
`
`
`
`
`
`
`
`
`
`
`The following officer/employees of FDA participated in the decision to
`
`
`
`
`
`
`
`
`
`
`approve this new drug application (NDA) and consented to be identified:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Abolade (Bola) Adeolu, RPh, MS, MBA
`
`
`
`John Amartey - PhD
`
`
`Todd Bourcier — PhD
`
`
`
`An'ane Conrad — PharmD
`
`
`Christian Cao — MPAS, PA-C
`
`
`Monika Houstoun— PharmD
`
`
`
`
`Shawn Hutchins — MSHS-PH, BSN, RN
`
`
`
`Anna Kettermann — PhD
`
`
`Anika Lalmansingh— PhD
`
`
`Christos Mastroyannis, MD
`
`
`
`Hina Mehta - PharmD
`
`
`
`
`Jennifer R Pippins - MD
`
`
`
`Frank Pucino — PharmD, MPH
`
`
`Suong Tran- PhD
`
`
`
`Jeffrey Quinn — PhD
`
`
`Mark D Rothmann — PhD
`
`
`Yun Wang — PhD
`
`
`
`Sharon Williams- MSA, BSN, RN
`
`
`
`
`
`Reference ID: 4069832
`Reference ID: 4069832
`
`(
`
`
`
`